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Management and Outcome of Permanent Pacemaker
and Implantable Cardioverter-Defibrillator Infections
Muhammad R. Sohail, MD,* Daniel Z. Uslan, MD,* Akbar H. Khan, MD,‡ Paul A. Friedman, MD,†
David L. Hayes, MD,† Walter R. Wilson, MD,* James M. Steckelberg, MD,* Sarah Stoner, MS,§
Larry M. Baddour, MD*
Rochester, Minnesota
Objectives We describe the management and outcome of permanent pacemaker (PPM) and implantable cardioverter-
defibrillator (ICD) infections in a large cohort of patients seen at a tertiary care facility with expertise in device
lead extraction.
Background Infection is a serious complication of PPM and ICD implantation. Optimal care of patients with these cardiac
device infections (CDI) is not well defined.
Methods A retrospective review of all patients with CDI admitted to Mayo Clinic Rochester between January 1, 1991, and
December 31, 2003, was conducted. Demographic and clinical data were collected, and descriptive analysis
was performed.
Results A total of 189 patients met the criteria for CDI (138 PPM, 51 ICD). The median age of the patients was 71.2
years. Generator pocket infection (69%) and device-related endocarditis (23%) were the most common clinical
presentations. Coagulase-negative staphylococci and Staphylococcus aureus, in 42% and 29% of cases, respec-
tively, were the leading pathogens for CDI. Most patients (98%) underwent complete device removal. Duration of
antibiotic therapy after device removal was based on clinical presentation and causative organism (median du-
ration of 18 days for pocket infection vs. 28 days for endocarditis; 28 days for S. aureus infection vs. 14 days for
coagulase-negative staphylococci infection [p  0.001]). Median follow-up after hospital discharge was 175
days. Ninety-six percent of patients were cured with both complete device removal and antibiotic administration.
Conclusions Cure of CDI is achievable in the large majority of patients treated with an aggressive approach of combined anti-
microbial treatment and complete device removal. Based on findings of our large retrospective institutional sur-
vey and previously published data, we submit proposed management guidelines of CDI. (J Am Coll Cardiol
2007;49:1851–9) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.072c
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Cith an increasing number of indications for use of permanent
acemakers (PPM) and implantable cardioverter-defibrillators
ICD), there has been an accelerated rate of device implanta-
ion (1,2). According to one estimate in the U.S., there was a
2% increase in the implantation rate of cardiac devices among
edicare beneficiaries from 1990 to 1999 (3). This was
ssociated with a 124% increase in the rate of cardiac device
nfection (CDI) among the study population.
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ardiology and infectious diseases specialists. Reported in-
idence rates of CDI range from 0.13% to 19.9% and 0.0%
o 0.8% for PPMs and ICDs, respectively (4–9). A CDI can
resent with a pulse-generator pocket infection or blood-
tream infection (BSI) with or without device-related en-
ocarditis. A CDI is complicated by increased morbidity,
ortality, and financial cost (10). Reported mortality rates
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Management of Cardiac Device Infections May 8, 2007:1851–9of cardiac device-related endo-
carditis range from 31% to 66% if
the infected device is not re-
moved, and 18% or less with a
combined management approach
with complete device removal and
antimicrobial therapy (11,12).
Estimated average cost of com-
bined medical and surgical treat-
ment of an infected device ranges
from $25,000 to $50,000 for
PPM and ICD, respectively
(13,14). Life-threatening com-
plications of device removal are
ell-reported (12,15,16).
To characterize the management and outcome of CDI,
e retrospectively reviewed 189 cases of CDI that presented
o Mayo Clinic Rochester between January 1991 and
ecember 2003.
ethods
e performed a retrospective review of the medical records
f patients with CDI treated at Mayo Clinic Rochester
etween January 1, 1991, and December 31, 2003. The
DI cases were identified using several Mayo Clinic re-
ources that included the Cardiology Device Database, the
urgical Index, and the computerized central diagnostic
ndex. All patients had consented to use of their medical
ecords for research purposes. The study proposal was
pproved by the Mayo Foundation Institutional Review
oard.
efinitions. A CDI was defined as previously described by
ur group and others (17–19). Clinical evidence of CDI
ncluded local signs of inflammation at the generator
ocket, including erythema, warmth, fluctuance, wound
ehiscence, erosion, tenderness, or purulent drainage. Pres-
nce of PPM/ICD-related endocarditis was clinically con-
rmed when valvular or lead vegetations were detected by
chocardiography, or if the Duke criteria for infective
ndocarditis were met (12,20). Vegetation was defined as an
scillating intracardiac mass on the electrode leads, cardiac
alve leaflets, or endocardial surface in the setting of valve or
ead infection confirmed by imaging in more than 1 echo-
ardiographic plane, and positive blood and/or lead tip
ultures (12,21–24).
A CDI was microbiologically confirmed based on positive
ultures from the generator pocket, lead(s), or blood (in the
resence of local inflammatory signs at generator pocket or
bsence of another source of bacteremia and resolution of
lood stream infection after device explantation). Relapse
as defined as the recurrence of the device infection with
ame organism, based on similar antibiogram.
ollow-up. Patients who presented with CDI and under-
ent device replacement procedure as part of their CDI
Abbreviations
and Acronyms
BSI  blood stream
infection
CDI  cardiac device
infection
CoNS  coagulase-negative
staphylococci
ICD  implantable
cardioverter-defibrillator
PPM  permanent
pacemakerreatment at Mayo Clinic Rochester had the option of being iollowed up at our institution or by their local health care
roviders. Of the 182 patients who survived index hospital-
zation for CDI, 142 patients (78%) chose follow-up at our
nstitution, whereas 40 (22%) patients had subsequent care
y their referring physician after discharge from Mayo
linic. Median follow-up duration for cases of CDI was
75 days (mean 657 days).
tatistical evaluation. The Fisher exact test was used to
est for differences in proportions for categorical data, and
he Wilcoxon rank-sum test was used to test for differences
n medians for continuous data. All p values were 2-sided
ith a level of 0.05 considered statistically significant. No
djustments for multiple comparisons were made. All anal-
ses were performed using SAS version 8.2 software (SAS
nstitute Inc., Cary, North Carolina).
esults
aseline characteristics. A total of 189 cases of CDI met
he case definition and were included in the study. Demo-
raphic and clinical characteristics of study subjects are
ummarized in Table 1. The median age of patients was
1.2 years (range 17 to 95 years). Seventy-eight percent
ere male. Devices included 138 PPMs and 51 ICDs. Most
atients (75%) had dual-chamber devices. Fifty-eight (31%)
atients had their cardiac devices implanted at Mayo Clinic
ochester, and 131 (69%) had device placement at another
nstitution. Transvenous lead placement (93%) was the most
ommonly used lead insertion technique. The pulse gener-
tor was placed in the pectoral area in 172 (91%) patients
nd in the abdominal wall in 17 (9%) patients. Indications
or initial device placement included heart block (38%),
inus node dysfunction (27%), and ventricular arrhythmias
21%). A CDI occurred after initial device implantation in
9 (42%) patients and after a revision (i.e., system upgrade,
ead revision, or generator exchange, and so on) in 110
58%).
linical presentation. Median time from device implan-
ation to infection was 415 days for PPM and 125 days for
CDs (p  0.009). Eighty-six (46%) patients initially
resented to Mayo Clinic Rochester, and 103 (54%) were
eferred to Mayo Clinic Rochester because of lack of
vailable expertise for lead extraction at the referring facility.
ocket infection, with (17%) or without (52%) BSI, was the
ost common clinical presentation, followed by device-
elated endocarditis (23%). Most patients had localized
nflammatory signs at the pocket site (Table 2). Systemic
igns of sepsis were present in less than one-half of the
ases. Ten (5%) cases presented with erosion of lead or
evice generator, without accompanying inflammatory signs
t the generator pocket site.
icrobiology. Coagulase-negative staphylococci (CoNS,
2%) and Staphylococcus aureus (29%) were the most com-
on causes of CDI, followed by gram-negative bacilli (9%),ncluding Klebsiella pneumoniae, Serratia marcescens, Pseudo-
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May 8, 2007:1851–9 Management of Cardiac Device Infectionsonas aeruginosa, Stenotrophomonas maltophilia, Acineto-
acter xylosoxidans, Acinetobacter baumanii, Citrobacter koseri,
organella morganii, Hemophilus influenzae, and Moraxella
atarrhalis (Fig. 1). Two patients had fungal (Candida
lbicans and Aspergillus fumigatus) infection. Polymicrobial
nfection was present in 7% of cases. Fourteen (7%) patients
ad localized inflammatory signs at generator pocket or
rosion of device/lead but pocket cultures were negative.
urulent material was encountered (intraoperative) within
he pulse-generator pocket in 151 (80%) of the cases (11%
f these patients had no inflammatory signs at the generator
ocket on physical examination). Seventy-five percent of the
emographic and Clinical Characteristics ofatients With CDI Who Were Trea d at Mayolinic Roc ester Between 1991 and 2003 (n  189)
Table 1
Demographic and Clinical Characteristics of
Patients With CDI Who Were Treated at Mayo
Clinic Rochester Between 1991 and 2003 (n  189)
Characteristic Value
Age (yrs), median (range) 71 (17–95)
Gender, male 148 (78%)
Device
PPM 138 (73%)
ICD 51 (27%)
Chambers
Single 44 (23%)
Dual 142 (75%)
Lead placement
Transvenous 176 (93%)
Epicardial 5 (3%)
Both 8 (4%)
Indication
Heart block 71 (38%)
Sinus node dysfunction 51 (27%)
Ventricular tachycardia/fibrillation 39 (21%)
Other 28 (14%)
Last procedure before CDI
De novo implantation 79 (42%)
System revision/upgrade 41 (22%)
Lead revision/insertion 19 (10%)
Generator replacement 49 (26%)
Time from implant/last intervention to infection, median
days (mean)
PPM 415 (920)
ICD 125 (399)
Comorbid conditions
Coronary artery disease 114 (60%)
Heart failure 96 (51%)
Anticoagulation 67 (35%)
Diabetes mellitus 46 (24%)
Chronic obstructive pulmonary disease 34 (18%)
Malignancy 24 (13%)
Clinical presentation
Pocket infection 99 (52%)
Pocket infection with bacteremia 32 (17%)
Device-related endocarditis 44 (23%)
Bacteremia without localizing signs at pocket 21 (11%)
Generator or lead erosion 10 (5%)DI  cardiac device infection; ICD  implantable cardioverter-defibrillator; PPM  permanent
acemaker.bove cases had positive cultures from the generator pocket.
lood cultures were positive in only 76 (40%) of all cases.
omplications of device infection. Complications of
DI included septic arthritis (n  6), vertebral osteomyeli-
is (n  2), sternal osteomyelitis (n  2), femoral osteomy-
litis (n  1), lung abscesses (n  5), splenic abscess (n  1),
Figure 1 Microbiology of PPM/ICD Infections (n  189)
ICD  implantable cardioverter-defibrillator; PPM  permanent pacemaker.
linical Presentation of Patients With CDI (n  189)
Table 2 Clinical Presentation of Patients With CDI (n  189)
Presenting Signs/Symptoms n (%)
Systemic symptoms
Fever (38°C) 82 (43)
Chills 73 (39)
Malaise 79 (42)
Anorexia 32 (17)
Nausea 16 (8)
Sweating 34 (18)
Hypotension (systolic blood pressure 90 mm Hg) 18 (10)
Murmur on examination 66 (35)
Symptomatic heart failure 52 (28)
Local findings at generator site
Erythema 128 (68)
Pain 93 (49)
Swelling 127 (67)
Warmth 71 (38)
Tenderness 86 (46)
Drainage 95 (50)
Purulent drainage 65 (34)
Skin ulceration 59 (31)
Generator/lead erosion 48 (25)
Intraoperative purulence at generator pocket 151 (80)
Laboratory abnormalities
Leukocytosis (WBC10  109/l), n  188 82 (43)
Anemia (HCT38% in men and35% in women), n  188 94 (50)
High erythrocyte sedimentation rate (ESR 22 mm/h in men
and29 mm/h in women), n  76
47 (25)
Positive blood culture (n  188) 76 (40)
DI  cardiac device infection; ESR  erythrocyte sedimentation rate; HCT  hematocrit; WBC 
hite blood cell count.
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Management of Cardiac Device Infections May 8, 2007:1851–9rain abscess (n  1), liver abscess (n  1), and perinephric
bscess (n  1). Twenty-two (11.6%) patients had throm-
osis of a vein where leads were in place (subclavian vein or
uperior vena cava), and in 6 of these cases, they presented
ith symptomatic pulmonary embolism. The majority of
atients (n  147, 78%) had an echocardiogram (transtho-
acic or transesophageal) performed, and 44 (23%) had
ither lead and/or valvular vegetations. The diameter of
egetations ranged from 0.3 to 7.0 cm in the longest
imension. It is noteworthy that none of these patients
eveloped clinical manifestations of pulmonary embolism as
complication of percutaneous lead extraction.
xplantation of infected devices. The cardiac device was
xplanted in 182 (96%) patients at the time of initial
resentation. Three (2%) other patients suffered relapsing
DI and had explantation after failure of conservative
medical) treatment. A cardiac device was not explanted in
patients because of high operative risk (advanced age and
ecompensated heart failure with ejection fraction 20%).
he entire device system was explanted in 178 (94%)
atients, whereas lead extraction was unsuccessful in 7 (4%)
ases. Most patients (90%) underwent percutaneous lead
xtraction with use of manual traction (15%), locking stylet
34%), or laser sheath (41%). Nineteen patients (10%) had
ead extraction via median sternotomy.
omplications of lead extraction. Twenty patients suf-
ered complications of percutaneous lead extraction (3
anual traction, 7 locking stylet, and 10 cases with laser
Figure 2 Timing of Reimplantation of New Cardiac Device and
Blue bars  time from explant to reimplant;  red bars  post-explant antibiotic durheaths), which included damage to the tricuspid valve (n
) that required valve annuloplasty in 2 patients, subclavian
ein laceration (n  3), hemothorax (n  4), pocket
ematoma (n  3), fracture of lead tip requiring surgical
ntervention (n  6), and massive hemorrhage that required
urgical intervention (n  5) and resulted in the death of 1
atient. Surgical removal of epicardial leads was complicated
y massive hemorrhage (n  2) that was lethal in 1 patient,
ostoperative cardiac arrest requiring intensive care unit stay
n  1), subclavian vein laceration (n  1), and ventricu-
otomy requiring operative repair (n  1). Complications
uring lead extraction were more common in patients with
istory of multiple device-related procedures (13 of 87,
4.9%) compared with those with initial implants (7 of 77,
.1%). However, this difference was not statistically signif-
cant (p  0.25).
ntimicrobial treatment. All patients received antimicro-
ials after removal or debridement of infected device system.
ost patients received at least 2 weeks of antibiotics after
emoval of an infected device (Fig. 2). Median duration of
ntibiotic treatment was significantly longer in patients with
. aureus infection as compared to those with CoNS (28
ays vs. 14 days, p  0.001). Patients with device-related
ndocarditis (valvular or lead vegetation) and BSI received a
edian of 28 days of antibiotics after device removal. Cases
ith ICD infection had a longer duration of antibiotics
median 22 days) as compared to those with PPM infection
median 16 days), but this difference was not statistically
ion of Postexplantation Antibiotic Treatment
CoNS  coagulase-negative staphylococci; other abbreviations as in Figure 1.Durat
ation.
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ombination of intravenous and oral antibiotics. Only 3%
ere treated with oral antibiotics alone. Adverse effects of
ntibiotic treatment included diarrhea (8%), nephrotoxicity
5%), neutropenia (2%), Clostridium difficile colitis (1%), and
ral candidiasis (1%).
eimplantation of a new device. All patients were as-
essed for ongoing need of a cardiac device after extraction
f an infected system. Reimplantation of a new device was
onsidered necessary in only 127 (67%) of the cases. Median
ime from explantation to reimplantation was significantly
onger for patients with BSI compared with nonbacteremic
ases (13 days vs. 7 days, p  0.0001). A new system was
laced as early as 3 days in cases of negative blood cultures
Fig. 2). The median time from explantation to reimplan-
ation in patients with CoNS was 7 days compared with a
elay of 12 days in cases of S. aureus infection (p 0.09). In
ases in which a new device system was implanted, most
atients (94%) had transvenous lead insertion with implan-
ation of a generator on the opposite side of the infected
ocket. Epicardial electrodes were placed in 7 (5%) patients.
enerator or lead erosion. Among our study subjects with
DI, 10 patients presented with generator or lead erosion
nly. Despite the absence of local inflammatory signs at the
ocket site, purulent material in the pulse-generator pocket
as noted intraoperatively in 3 (30%) of these cases, and 9
90%) had positive cultures from an intraoperative swab of
he pocket. The causative micro-organism for CDI in this
roup of patients included common skin flora such as CoNS
n  4), S. aureus (n  3), and Propionibacterium spp. (n 
), whereas 1 patient had polymicrobial infection with
oNS, Propionibacterium spp., and Corynebacterium spp. All
atients had explanation of the infected device at the initial
resentation (complete hardware successfully removed in 9
ases, whereas percutaneous lead extraction was unsuccess-
ul in 1 case). Median time from removal of an infected
evice to insertion of a new system was 3 days. Among cases
n  7) with no intraoperative evidence of purulence in the
enerator pocket, 4 (57%) had a new system placed on the
ame day when the infected device was removed. All
atients were cured and none had infection relapse at their
ast follow-up visit (mean duration 78 weeks).
utcome. The average duration of hospitalization for CDI
as 17 days (median 13 days). Seven patients died during
ndex hospitalization for CDI. Of the remaining 182 cases,
ollow-up data were available for 142 cases (40 patients were
ollowed up elsewhere). Most patients (135, 95%) re-
ained free of infection, after the initial treatment, at the
ast follow-up (median follow-up duration 175 days; mean
57 days). Two patients had persistent pocket infection
aused by retained hardware. Five cases presented with
elapse of infection. Clinical characteristics, microbiology,
anagement, and outcome of these 5 cases are summarized
n Table 3. Two of these patients were subsequently cured
ith complete removal of the infected device. Ch T
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Management of Cardiac Device Infections May 8, 2007:1851–9There were 9 in-hospital deaths, 7 during index hospi-
alization and 2 in patients who were subsequently hospi-
alized for relapse of infection. Five of these patients had
evice-related endocarditis (4 with staphylococci and 1 with
spergillus fumigatus). Staphylococcal BSI with sepsis (n 
) was the most common cause of death. Two patients died
econdary to complications of device extraction surgery.
ne patient died of ventilator-associated pneumonia during
n intensive care unit stay after device removal. One severely
mmunocompromised patient with device-related fungal
ndocarditis and metastatic abscesses died.
Seven patients had partial device explantation at initial
resentation. Two were lost to follow-up after the index
ospitalization (both cases had abandoned epicardial leads
rom previous devices, and the currently infected devices
ad transvenous leads that were removed along with gen-
rators). One patient died of surgical complications during
second attempt at complete hardware removal. Of the
emaining 4 patients, 2 had a relapse (Table 3, cases 2 and
). The other 2 patients remained infection-free despite only
artial device removal. Both had negative blood cultures and
o evidence of endocarditis on echocardiography. Percutane-
us lead extraction was attempted but was unsuccessful in first
atient with pocket infection. Transvenous lead removal was
ot attempted in the second case because of absence of
nflammatory changes during generator pocket exploration. In
oth cases, there was no evidence of infection at their last
ollow-up visit (5 months in the case of pocket infection and 4
ears in the case of generator erosion only).
iscussion
espite improvements in the design and implantation
echniques, infection of the cardiac devices remains a serious
roblem. The current study is one of the largest reported
eries of CDI in the United States and the only one to
ropose management guidelines.
linical presentation and microbiology. There was con-
iderable variation in time from device implantation to onset
f infection in our survey. Median time from implantation
o infection was shorter for ICDs (125 days) than for PPMs
414 days). This time difference between the 2 groups may
n part be caused by an increased proportion of S. aureus
nfection in patients with an ICD (35%) as compared to
hose with PPM (26%). Patients with PPM infection were
ore likely to have CoNS isolated (46%) from blood or
ocket cultures than those with an ICD (31%).
Most patients with CDI present with only localized
nflammatory signs at the generator pocket (Table 2), and a
ack of systemic signs should not sway clinicians away from
suspicion of CDI (19). Nonspecific laboratory abnormal-
ties such as leukocytosis, anemia, and high sedimentation
ate were present in less than one-half of the cases in the
urrent study. Staphylococcal species account for more than
wo-thirds of CDI cases in most published series
11,12,15,19,25) and were predominant in the present inves- Higation (Fig. 1). Therefore, empiric antibiotics for suspected
DI should include coverage for staphylococci while await-
ng microbiology results.
onservative treatment versus complete device removal.
ome investigators have advocated conservative treatment with
ntibiotics and generator pocket debridement without hard-
are removal (26–28). Most previously published studies,
owever, have shown unacceptably high failure rates with
onservative treatment (11–13,19,22,23,29–35).
The Heart Rhythm Society guidelines state that extrac-
ion of an entire lead may not be necessary if the lead can be
ut through a sterile incision, totally separate from an
nfected pocket (36). However, the intracardiac portion of a
ead may be colonized in cases in which CDI findings are
imited to the pulse-generator pocket only (13,25,37), and
here is a high risk of treatment failure with a lead-retention
pproach as recommended by the Heart Rhythm Society
25,34,38–41). In the current study, 5 patients had CDI
elapse (2.6%), and 3 of them had only partial explantation
f the device (generator only) at initial presentation. The
ther 2 patients had a temporary pacing wire as a bridge
etween explantation of an infected device and reimplanta-
ion of a new device. Use of the temporary pacing wires has
een identified as a risk factor for subsequent CDI in 2
ecent studies (42,43). Based on the above findings, we
ecommend complete hardware removal to achieve CDI
ure; this mirrors the recommendations of the American
eart Association (4).
ercutaneous versus surgical lead extraction. Extraction
f cardiac device leads is not without risk (16,31,40).
espite advances in techniques for percutaneous lead ex-
raction (44), there is still considerable morbidity and
ortality associated with this procedure. In our study, 20
atients (11%) had complications of percutaneous lead
xtraction that included damage to cardiac valves, venous
acerations, bleeding complications, and lead tip fracture
hat required surgical intervention. Some investigators have
xpressed concern about transvenous lead removal when
ead vegetation size is 1 cm because of the risk of
ulmonary embolization of lead vegetation fragments
12,45–47). No patient had a clinically significant pulmo-
ary embolism in our series despite the presence of vegeta-
ion sizes that ranged from 0.3 to 7.0 cm in the longest
imension. Others have reported similar experiences
22,23,48,49). Lead removal by cardiotomy (50,51) has been
dvocated to prevent symptomatic pulmonary embolism but, as
hown in the current case series, this approach can be compli-
ated by serious adverse events. Five patients suffered massive
emorrhages postoperatively, and 1 died in our series.
uration of antimicrobial treatment. The duration of anti-
icrobial treatment for CDI depended on the clinical presen-
ation and the causative agent. In a large case series from the
leveland Clinic Foundation (19), the median duration of
ntibiotic treatment in CDI cases with pocket infection and
hose with bacteremia was 26 days and 41 days, respectively.owever, in our practice, cases of CDI with only pocket
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May 8, 2007:1851–9 Management of Cardiac Device Infectionsnfection were treated with 10 to 14 days of antimicrobials and
hose with BSI for 4 weeks after device removal. Similarly,
atients with cardiac device-related endocarditis limited to the
ight heart can be treated with 4 weeks of antibiotics instead of
he 6-week treatment course that has been advocated by some
12,13,19). Infection by certain microorganisms may require
onger antimicrobial treatment for complete eradication of a
DI. In our study, cases of CDI attributable to S. aureus had
Figure 3 Mayo Clinic Algorithm of Cardiac Device Infection Ma
(A) Approach to management of adults with PPM/ICD infection (also see Table 4).
*Duration of antibiotics should be counted from the day of device explantation. (B
also Table 4). AHA  American Heart Association; TEE  transesophageal echocaignificantly longer treatment after device explantation as
ompared to those with CoNS infection (28 days vs. 14 days,
 0.001). An S. aureus CDI is also associated with a higher
ortality rate as compared with that caused by other pathogens.
n our study, there were 9 in-hospital deaths (crude mortality rate
.7%), and 5 had S. aureus identified in blood cultures.
iming and need of a replacement device. Timing of
eimplantation of a new device system after extraction of
ment
lgorithm applies only to the patients with complete device explantation.
elines for reimplantation of new device in patients with PPM/ICD infection (see
phy; other abbreviations as in Figure 1.nage
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Management of Cardiac Device Infections May 8, 2007:1851–9n infected device remains a subject of debate and is
nfluenced by the causative agent and clinical presenta-
ion of CDI. Median time from explantation to reim-
lantation of a new device was significantly longer for
atients with BSI as compared to those with negative
lood cultures (13 days vs. 7 days, p  0.0001) in the
urrent investigation. There was no statistically signifi-
ant difference in time from explant to reimplant in
atients with CoNS infection (median 7 days) as com-
ared to those with S. aureus infection (median 12 days,
 0.09). Although some investigators (13) have sug-
ested delaying reimplantation of new device for 10 to 14
ays in cases of pocket infection (without BSI) and up to
weeks in bacteremic patients, our data suggest that
evices can be safely reimplanted once the pocket has
een adequately debrided and blood cultures are negative.
hese data are consistent with previously published
eports (19). Moreover, maintaining a transvenous tem-
orary device increases the risk of subsequent CDI
43,52) and cannot be used indefinitely.
The need for placement of a new device system should be
arefully assessed in all patients with CDI because an
ppreciable number of patients may not require a subse-
uent cardiac device. Discontinuation of electrophysiologic
evice use after removal of an infected system has been
eported in 13% to 52% of cases (11,19,30,53). In our study,
eimplantation of a new device was not required in one-
hird of patients.
roposed Mayo Clinic guidelines for management of
DI. Based on the findings of our retrospective analysis
nd review of published literature (1–53), we propose guide-
ines for CDI (Figs. 3A and 3B, Table 4) to assist clinicians in
atient management. These recommendations are not meant
o replace individual patient management, however, and con-
ultation with available specialists is advocated.
tudy limitations. Our investigation has several limita-
ions. First, retrospective studies have inherent limitations,
ayo Clinic Guidelines for the Diagnosis and Management of Cardi
Table 4 Mayo Clinic Guidelines for the Diagnosis and Managem
1. All patients should have at least 2 sets of blood cultures drawn at initial evaluat
2. Generator tissue Gram stain and culture and lead tip culture should be obtained
3. Patients who either have positive blood cultures or have negative blood cultures
transesophageal echocardiogram (TEE) to assess for device-related endocarditis
4. Sensitivity of TTE is low and is not recommended to evaluate for device-related e
5. Patients with negative blood cultures and recent prior antibiotics and valve vege
6. All patients with device infection should undergo complete device removal, rega
7. A large (1 cm) lead vegetation is not a stand alone indication for surgical lead
8. Blood cultures should be repeated in all patients after device explantation. Patie
antimicrobials even if TEE is negative for vegetations or other evidence of infect
9. Duration of antimicrobial therapy should also be extended to 4 weeks in patie
metastatic seeding).
10. Adequate debridement and control of infection should be achieved at all sites b
11. Reevaluation for continued need of the device should be performed before new
12. If an infected cardiac device cannot be removed, than long-term suppressive an
and securing a clinical response to therapy. Infectious diseases expert opinion such as potential selection and recall biases. Second, Mayolinic Rochester is a tertiary referral center with referral
ias, as was shown in the current survey. Patients who are
eferred to a specialized cardiovascular center may be sicker
nd have more complex cardiac devices than the general
opulation. Third, the majority of our cohort was white
91%), and this reflected both local population demograph-
cs and the referral population. Despite these limitations,
ata presented herein provide critical information to clini-
ians who manage CDI.
onclusions. A CDI is an important and serious compli-
ation of device use. Because of the expected continued
ncrease in the number of cases of CDI and the current lack
f prospective, randomized trial data to assist in defining
ptimal treatment, we present proposed guidelines to assist
linicians in the management of CDI.
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